Literature DB >> 17917491

T-wave amplitude attenuation/augmentation in patients with changing edematous states: implications for patients with congestive heart failure.

John E Madias1.   

Abstract

Since peripheral edema impacts the entire electrocardiographic curve, it was hypothesized that it would also affect T waves. The amplitude of T waves were measured in all electrocardiographic leads and a sum (SigmaT) was calculated in 28 patients with and 28 patients without peripheral edema (controls). For patients with peripheral edema, SigmaT on admission was 21.9+/-10.6 mm and SigmaT at peak weight was 8.3+/-6.3 mm (P=.0005). For patients with peripheral edema who subsequently lost weight, SigmaT at peak weight was 7.2+/-6.1 mm and SigmaT at the lowest weight was 14.1+/-12.2 (P=.006). For controls, SigmaT from admission and SigmaT from discharge were 24.4+/-16.9 mm and 24.7+/-15.7 mm (P=.82), respectively. Percent change (Delta%SigmaT) from admission to peak weight correlated with Delta% in weight (r=0.58; P=.001) and Delta% in the sum of QRS complexes (SigmaQRS) (r=0.71; P=.00005). Delta%SigmaT from peak weight to the lowest weight correlated with the corresponding Delta%SigmaQRS (r=0.65; P=.02). Changes in T waves with development and alleviation of peripheral edema mirror the changes shown by the QRS complexes and may be useful in the treatment of patients with congestive heart failure or other edematous states.

Entities:  

Mesh:

Year:  2007        PMID: 17917491     DOI: 10.1111/j.1527-5299.2007.06212.x

Source DB:  PubMed          Journal:  Congest Heart Fail        ISSN: 1527-5299


  2 in total

1.  Electrocardiogram voltage attenuation and shortening of the duration of P-waves, QRS complexes, and QT intervals.

Authors:  John E Madias
Journal:  Indian Heart J       Date:  2013-09-04

2.  The need for studies to evaluate the reproducibility of the T-wave alternans (TWA), and the rationale for a correction index of the TWA.

Authors:  John E Madias
Journal:  Indian Pacing Electrophysiol J       Date:  2007-08-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.